PDS Biotechnology Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
PDS Biotechnology Corp (PDSB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.01% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-30
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-09-30 was 0.00%, a 100.00% decline year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.26%, a 18.66% increase year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.98%, a 1.97% decline year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 3.92%, a 29.37% increase year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.01%, a 0.74% decline from fiscal 2024.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.04%, a 2.42% decline from fiscal 2023.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.14%, a 131.28% increase from fiscal 2022.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.79%, a 265.31% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 4.01% 10-K · filed 2026-03-30 | |||||||
| 2024-12-31 | 4.04% 10-K · filed 2026-03-30 | |||||||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-14 | 4.04% 10-Q · filed 2024-11-14 | ||||||
| 2024-06-30 | 4.26% 10-Q · filed 2024-08-13 | 4.04% 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | 3.98% 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | 4.14% 10-K · filed 2025-03-27 | |||||||
| 2023-09-30 | 3.92% 10-Q · filed 2024-11-14 | 4.04% 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | 3.59% 10-Q · filed 2024-08-13 | 4.05% 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | 4.06% 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | 1.79% 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 3.03% 10-Q · filed 2023-11-14 | 1.70% 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | 2.60% 10-Q · filed 2023-08-14 | 11.62% 10-Q · filed 2023-08-14 | 1.62% 10-Q · filed 2022-08-08 | |||||
| 2022-03-31 | 1.10% 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 0.49% 10-K · filed 2023-03-28 | |||||||
| 2021-09-30 | 0.77% 10-Q · filed 2022-11-14 | 55.88% 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | 0.79% 10-Q · filed 2022-08-08 | 0.72% 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | 0.35% 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | 0.39% 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | 0.38% 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | 0.34% 10-Q · filed 2021-08-12 | 0.38% 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | 1.56% 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | 2.31% 10-K · filed 2021-03-18 | |||||||
| 2019-09-30 | 1.49% 10-Q · filed 2020-11-13 | 2.33% 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | 2.19% 10-Q · filed 2020-08-13 | 2.34% 10-Q · filed 2020-08-13 | ||||||
| 2019-03-31 | 2.49% 10-Q · filed 2020-05-13 | |||||||
| 2019-03-13 | 2.63% 10-K · filed 2021-03-18 | |||||||
| 2018-12-31 | 2.23% 10-K · filed 2019-02-21 | |||||||
| 2018-09-30 | 2.75% 10-Q · filed 2019-11-07 | 0.00% 10-Q · filed 2018-11-01 | 2.75% 10-Q · filed 2019-11-07 | 2.31% 10-Q · filed 2018-11-01 | ||||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-01 | 2.27% 10-Q · filed 2018-08-01 | 0.00% 10-Q · filed 2019-08-01 | 2.31% 10-Q · filed 2018-08-01 | ||||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-14 | 2.34% 10-Q · filed 2018-05-01 | ||||||
| 2017-12-31 | 1.88% 10-K · filed 2019-02-21 | |||||||
| 2017-09-30 | 1.83% 10-Q · filed 2018-11-01 | 1.89% 10-Q · filed 2018-11-01 | ||||||
| 2017-06-30 | 1.84% 10-Q · filed 2018-08-01 | 1.89% 10-Q · filed 2018-08-01 | ||||||
| 2017-03-31 | 1.90% 10-Q · filed 2018-05-01 | |||||||
| 2016-12-31 | 1.39% 10-K · filed 2018-03-01 | |||||||
| 2016-09-30 | 1.19% 10-Q · filed 2017-11-01 | 1.38% 10-Q · filed 2017-11-01 | ||||||
| 2016-06-30 | 1.29% 10-Q · filed 2017-08-01 | 1.39% 10-Q · filed 2017-08-01 | ||||||
| 2016-03-31 | 1.41% 10-Q · filed 2017-05-03 | |||||||
| 2015-12-31 | 1.74% 10-K · filed 2018-03-01 | |||||||
| 2015-09-30 | 1.59% 10-Q · filed 2016-11-01 | 1.74% 10-Q · filed 2016-11-01 | ||||||
| 2015-06-30 | 1.58% 10-Q · filed 2016-08-03 | 1.79% 10-Q · filed 2016-08-03 | ||||||
| 2015-03-31 | 1.82% 10-Q · filed 2016-05-03 | |||||||
| 2014-12-31 | 1.96% 10-K · filed 2017-03-02 | |||||||
| 2014-09-30 | 1.88% 10-Q · filed 2015-11-06 | 1.96% 10-Q · filed 2015-11-06 | ||||||
| 2013-12-31 | 1.76% 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |